ObsEva SA (OBSV)
Chart Events
Performance Outlook
| Previous Close | 1.6700 |
| Open | 1.7600 |
| Bid | 1.7300 x 1800 |
| Ask | 1.7400 x 1100 |
| Day's Range | 1.6400 - 1.8000 |
| 52 Week Range | 1.0800 - 3.5800 |
| Volume | |
| Avg. Volume | 505,995 |
| Market Cap | 135.67M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8220 |
| Earnings Date | Mar 03, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.38 |
- GlobeNewswire
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th World Congress- GENEVA, Switzerland May 25, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist. These data were featured in
- Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual MeetingGlobeNewswire
- Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual MeetingGlobeNewswire
- GlobeNewswire
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva’s Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decide
- GlobeNewswire
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022. The approved items are as follows: Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial
